- Home
- CRNC vs VERV Comparison
CRNC vs VERV Comparison
Compare CRNC & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNC
- VERV
- Stock Information
- Founded
- CRNC 2020
- VERV 2018
- Country
- CRNC United States
- VERV United States
- Employees
- CRNC N/A
- VERV N/A
- Industry
- CRNC EDP Services
- VERV Medicinal Chemicals and Botanical Products
- Sector
- CRNC Technology
- VERV Health Care
- Exchange
- CRNC Nasdaq
- VERV Nasdaq
- Market Cap
- CRNC 445.8M
- VERV 384.2M
- IPO Year
- CRNC N/A
- VERV 2021
- Fundamental
- Price
- CRNC $8.51
- VERV $4.45
- Analyst Decision
- CRNC Buy
- VERV Strong Buy
- Analyst Count
- CRNC 7
- VERV 6
- Target Price
- CRNC $9.43
- VERV $25.75
- AVG Volume (30 Days)
- CRNC 1.1M
- VERV 2.9M
- Earning Date
- CRNC 05-07-2025
- VERV 05-14-2025
- Dividend Yield
- CRNC N/A
- VERV N/A
- EPS Growth
- CRNC N/A
- VERV N/A
- EPS
- CRNC N/A
- VERV N/A
- Revenue
- CRNC $254,250,000.00
- VERV $59,613,000.00
- Revenue This Year
- CRNC N/A
- VERV $6.18
- Revenue Next Year
- CRNC $7.31
- VERV N/A
- P/E Ratio
- CRNC N/A
- VERV N/A
- Revenue Growth
- CRNC N/A
- VERV 271.44
- 52 Week Low
- CRNC $2.34
- VERV $2.87
- 52 Week High
- CRNC $27.50
- VERV $9.31
- Technical
- Relative Strength Index (RSI)
- CRNC 45.71
- VERV 47.78
- Support Level
- CRNC $8.45
- VERV $3.89
- Resistance Level
- CRNC $9.05
- VERV $4.63
- Average True Range (ATR)
- CRNC 0.52
- VERV 0.41
- MACD
- CRNC -0.10
- VERV 0.02
- Stochastic Oscillator
- CRNC 19.43
- VERV 47.06
About CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.